Donepezil Viatris (Donepezil Hydrochloride)

Donepezil Viatris is indicated for the symptomatic treatment of mild to moderate Alzheimer’s disease.

• Improves cognitive function such as memory, attention, and language.
• Supports activities of daily living by enhancing neuronal communication.
• May be used as part of a comprehensive care plan that includes non‑pharmacologic interventions.
• Can be considered when a clinician determines that cholinergic augmentation is appropriate for a patient with diagnosed Alzheimer’s disease.
• May be prescribed when other symptomatic treatments are insufficient or not tolerated.
• Dosage adjustments may be considered based on renal function and patient response, following physician guidance.

The safety profile of Donepezil Viatris includes a range of adverse effects that have been reported in clinical use.

Common

• Nausea and vomiting, often occurring during the first weeks of treatment.
• Diarrhea or loose stools, which may be mild to moderate.
• Insomnia or vivid dreams, reflecting central cholinergic activity.
• Muscle cramps, fatigue, or generalized weakness.
• Decreased appetite leading to mild weight loss.
• Dizziness or light‑headedness, particularly when standing.

Serious

• Bradycardia, heart block, or other clinically significant slowing of heart rate.
• Severe gastrointestinal bleeding or ulceration.
• Elevated liver enzymes indicating possible hepatotoxicity.
• Seizures, especially in patients with a history of epilepsy.
• Allergic reactions such as rash, pruritus, or angioedema.

When prescribing Donepezil Viatris, clinicians should consider several precautionary measures to ensure patient safety.

• Assess cardiac history, including bradyarrhythmias, before initiating therapy.
• Review concomitant use of other cholinergic or anticholinergic agents.
• Monitor liver function tests periodically during treatment.
• Use caution in patients with severe renal impairment; dose adjustment may be required.
• Evaluate for gastrointestinal disorders such as ulcer disease or reflux.
• Consider the risk of falls in elderly patients due to dizziness.
• Discuss potential pregnancy and lactation considerations, as safety data are limited.

Donepezil Viatris may interact with other medicines, influencing its efficacy or safety.

Avoid

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that can increase donepezil plasma levels.
• Anticholinergic drugs (e.g., diphenhydramine, atropine) that may reduce therapeutic effect.

Use with caution

• Beta‑blockers or other agents that lower heart rate, due to additive bradycardia risk.
• NSAIDs or anticoagulants, which may raise the risk of gastrointestinal bleeding.
• Other acetylcholinesterase inhibitors, as combined use can increase cholinergic side effects.
• Drugs that affect hepatic metabolism (e.g., rifampin) potentially altering donepezil clearance.
• Sedatives or hypnotics, as insomnia may be exacerbated.